Collaboration includes the initial program utilizing Icagen’s Drug Discovery Platform.
DURHAM, NC, USA I December 5, 2018 I Icagen announced today that they have entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders. The program incorporates Icagen’s platform for ion channels and is directed at a specific novel ion channel target expressed in neurons.
“We are excited about partnering with Roche to develop treatments for difficult to treat neurological diseases and look forward to collaborating with them to help bring medicines to patients,” said Icagen CEO Richie Cunningham. “Roche has a great track record of partnering with biotech firms in addition to unique development expertise and a strong global commercial presence. This collaboration is a great example of combining Icagen’s depth and expertise in ion channel drug discovery with the therapeutic area and developmental expertise of a company like Roche to enhance the likelihood of identifying meaningful new therapies.”
Terms of Collaboration
Under the terms of the agreement, Roche will make a cash upfront payment and provide research funding to Icagen. In addition, Icagen is eligible to potentially receive development and commercial milestone payments of up to $274 million and royalty payments should a drug be commercialized.
Icagen will be responsible for all preclinical activities up to lead optimization with both Icagen and Roche applying resources to identify candidates for entry into IND-enabling studies. Roche will be responsible for the further development and commercialization of the program.
About Icagen
Icagen is an early drug discovery company focused on Neuroscience and Rare Disease with research facilities located in Durham, N.C. and Oro Valley, AZ. We partner with the pharmaceutical industry to develop first in class therapies for patients in need whereby we do the drug discovery and our partners fund the clinical development and commercialization. For more information, visit www.icagen.com.
SOURCE: Icagen
Post Views: 492
Collaboration includes the initial program utilizing Icagen’s Drug Discovery Platform.
DURHAM, NC, USA I December 5, 2018 I Icagen announced today that they have entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders. The program incorporates Icagen’s platform for ion channels and is directed at a specific novel ion channel target expressed in neurons.
“We are excited about partnering with Roche to develop treatments for difficult to treat neurological diseases and look forward to collaborating with them to help bring medicines to patients,” said Icagen CEO Richie Cunningham. “Roche has a great track record of partnering with biotech firms in addition to unique development expertise and a strong global commercial presence. This collaboration is a great example of combining Icagen’s depth and expertise in ion channel drug discovery with the therapeutic area and developmental expertise of a company like Roche to enhance the likelihood of identifying meaningful new therapies.”
Terms of Collaboration
Under the terms of the agreement, Roche will make a cash upfront payment and provide research funding to Icagen. In addition, Icagen is eligible to potentially receive development and commercial milestone payments of up to $274 million and royalty payments should a drug be commercialized.
Icagen will be responsible for all preclinical activities up to lead optimization with both Icagen and Roche applying resources to identify candidates for entry into IND-enabling studies. Roche will be responsible for the further development and commercialization of the program.
About Icagen
Icagen is an early drug discovery company focused on Neuroscience and Rare Disease with research facilities located in Durham, N.C. and Oro Valley, AZ. We partner with the pharmaceutical industry to develop first in class therapies for patients in need whereby we do the drug discovery and our partners fund the clinical development and commercialization. For more information, visit www.icagen.com.
SOURCE: Icagen
Post Views: 492
